HedgePath Pharmaceuticals Secures Interim Financing To Commence Clinical Trials and Finalizes Key Agreement with Mayne Pharma

   HedgePath Pharmaceuticals Secures Interim Financing To Commence Clinical
             Trials and Finalizes Key Agreement with Mayne Pharma

$1.5 million in proceeds to fund 2014 commencement of HPPI's clinical
development program for repurposing the approved anti-fungal drug itraconazole
for the treatment of cancer, initially for the treatment of Basal Cell
Carcinoma Nevus Syndrome

Mayne Pharma has acquired a significant minority stake in HPPI and, per
previous agreement, will serve as HPPI's itraconazole manufacturer and
supplier

PR Newswire

TAMPA, Fla. and SAN DIEGO, June 25, 2014

TAMPA, Fla. and SAN DIEGO, June 25, 2014 /PRNewswire/ -- HedgePath
Pharmaceuticals, Inc. (OTCQB:HPPI) a clinical stage biopharmaceutical company
that discovers, develops and plans to commercialize innovative therapeutics
for patients with cancer, announced today that it has closed a $1.5 million
interim private common stock financing. The funds were secured from
Hedgepath, LLC, HPPI's current majority stockholder. Under the terms of the
financing, Hedgepath, LLC will purchase 20 million shares of HPPI common stock
for gross proceeds of $1.5 million, which proceeds will be funded in
pre-agreed to monthly tranches during the remainder of 2014.

Concurrently with this funding, HPPI has finalized its previously announced
Supply and License Agreement with Mayne Pharma Ventures Pty Ltd (Mayne
Pharma), a wholly owned subsidiary of Mayne Pharma Group Limited, an
Australian Stock Exchange listed company. Under related agreements entered
into by HPPI and Mayne Pharma to finalize the Supply and License Agreement,
Mayne Pharma has acquired shares of HPPI preferred stock and warrants to
acquire HPPI common stock amounting to an approximately 40% fully diluted
equity interest in HPPI.

HPPI is using the proceeds of the financing to support its filing of an
Investigational New Drug (IND) Application aimed at securing FDA approval to
begin a corporate-sponsored clinical trial with HPPI's primary drug candidate,
SUBA™-Itraconazole for the treatment of basal cell carcinoma (BCC), and to
commence and conduct such trial. HPPI holds the exclusive U.S. rights to
SUBA-Itraconazole from Mayne Pharma for the treatment of cancer. Mayne Pharma
will also supply SUBA-Itraconazole for HPPI's currently contemplated and
future clinical trials.

HPPI intends to study the anti-cancer efficacy of SUBA-Itraconazole as a
Hedgehog pathway inhibitor in a Phase II(b) trial as a treatment for BCC with
a focus on seeking eventual regulatory approvals and marketing in the United
States. SUBA-Itraconazole capsules will be tested as a stand-alone, daily
oral therapy for treatment of BCC, with an initial emphasis on patients with
BCCNS (basal cell carcinoma nevus syndrome, also known as Gorlin-Goltz
Syndrome), for which HPPI intends to file for orphan drug designation. This
initial effort in BCC is then expected to be expanded during 2015 to include
non-BCCNS patients with poorly operable basal cell tumors to determine if, as
may be the case for treatment of patients with BCCNS, a treatment that is less
toxic than the currently approved Hedgehog inhibitor will be better suited as
a chronic therapy for recurring tumors.

Earlier this month, HPPI began formal interaction with FDA and clinical
investigators regarding an IND for BCCNS. Assuming FDA concurrence with its
plans, HPPI intends to commence this first clinical trial in BCC during
October 2014.

Nicholas J. Virca, HPPI's president and chief executive officer, stated that,
"This is a milestone moment for our company. Our binding agreement with Mayne
Pharma and our interim financing enables us to initiate our clinical programs
designed around the re-purposing of itraconazole, which is an FDA approved
anti-fungal drug, for new therapies in the treatment of cancer. We believe
the patent-protected formulation of SUBA-Itraconazole will enhance clinical
performance through improved drug delivery, at nearly twice the
bioavailability of generic formulations of itraconazole, and enable low
toxicity, chronic dosing that will achieve predictable therapeutic blood
levels better suited for oncology applications, such as the daily dosing of
patients with BCCNS who face the ongoing development of tumors throughout
their lifetime. We are very excited to move forward with our IND and to begin
our clinical trial work."

Also as part of these transactions, Hedgepath, LLC has agreed to forgive or
exchange approximately $640,000 of advances previously made to HPPI in
consideration of the issuance to Hedgepath, LLC of shares of HPPI preferred
stock and common stock and warrants to purchase common stock. Following this
transaction, and assuming full funding of its $1.5 million investment,
Hedgepath, LLC owns an approximately 46.5% fully diluted interest in HPPI.

Additional details regarding the terms of the financing and the Mayne Pharma
agreements will be made available in a Current Report on Form 8-K to be filed
by HPPI with the Securities and Exchange Commission.

About HedgePath Pharmaceuticals

HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI) is a clinical stage
biopharmaceutical company that is seeking to repurpose the FDA approved
antifungal pharmaceutical itraconazole as a potential treatment for cancer.
HPPI is the exclusive U.S. licensee of a patented formulation of itraconazole,
called SUBA-Itraconazole, which clinical studies have shown to have greater
bioavailability than generic itraconazole.

The Hedgehog signaling pathway is a major regulator of cellular processes in
vertebrates, including cell differentiation, tissue polarity and cell
proliferation. Based on published research, HPPI believes that inhibiting the
Hedgehog pathway could delay or possibly prevent the development of certain
cancers in humans. Itraconazole has also been shown to exhibit
anti-angiogenic properties (inhibiting the formation of new blood vessels in
tumors) which can also impact the progression of certain cancers. Leveraging
research undertaken by key investigators in the field, HPPI plans to explore
the effectiveness of SUBA-Itraconazole as a cancer inhibitor and to pursue its
potential commercialization. HPPI has offices in Tampa, Florida and San
Diego, California. For more information, please visit
www.hedgepathpharma.com.

Cautionary Note Regarding Forward Looking Statements

This press release and any statements of representatives and partners of
HedgePath Pharmaceuticals, Inc. (the "Company") related thereto contain, or
may contain, among other things, certain "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve significant risks and uncertainties. Such
statements may include, without limitation, statements with respect to the
Company's plans, objectives, projections, expectations and intentions and
other statements identified by words such as "projects," "may," "will,"
"could," "would," "should," "believes," "expects," "anticipates," "estimates,"
"intends," "plans," "potential" or similar expressions. These statements are
based upon the current beliefs and expectations of the Company's management
and are subject to significant risks and uncertainties, including those
detailed in the Company's filings with the Securities and Exchange
Commission. Actual results (including, without limitation, the timing for and
results of the Company's anticipated clinical trials) may differ significantly
from those set forth in the forward-looking statements. These forward-looking
statements involve certain risks and uncertainties that are subject to change
based on various factors (many of which are beyond the Company's control).
The Company undertakes no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events or
otherwise, except as required by applicable law.

For more information:

Company Contact:
HedgePath Pharmaceuticals, Inc., Nicholas J. Virca, President and CEO,
813-864-2559, nvirca@hedgepathpharma.com.

Investor Relations:
HedgePath Pharmaceuticals, Inc., Garrison Hasara, CFO and Treasurer,
813-864-2560,
ghasara@hedgepathpharma.com

© 2014 HedgePath Pharmaceuticals, Inc. All rights reserved.

SOURCE HedgePath Pharmaceuticals, Inc.

Website: http://www.hedgepathpharma.com
 
Press spacebar to pause and continue. Press esc to stop.